207_Combined course Presentations

Overall population



TREATMENT: 1. HD-MTX + Procarbazine + Ara-C 2. Eventual WBI: 45 Gy

 30% of patients developed treatment-related neurotoxicity after WBI.

1. Pts >60 years: 75% (9/12). 2. Pts <60 years: 26% (5/19).

 Only one patient developed neurotoxicity after chemotherapy alone; this patient had an initial KPS of 40 with poor recovery of function and possible MTX- induced leukoencephalopathy.

 The median survival from diagnosis of neurotoxicity was 23 months.

N.B. formal neuropsychological testing was not performed